36147
2-甲-4-氯丙酸
PESTANAL®, analytical standard
别名:
2-(4-氯-2-甲基苯氧基)丙酸
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C10H11ClO3
化学文摘社编号:
分子量:
214.65
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
202-264-4
Beilstein/REAXYS Number:
6568283
MDL number:
grade
analytical standard
Quality Level
product line
PESTANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
agriculture
environmental
format
neat
SMILES string
CC(Oc1ccc(Cl)cc1C)C(O)=O
InChI
1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)
InChI key
WNTGYJSOUMFZEP-UHFFFAOYSA-N
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Legal Information
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 2-甲-4-氯丙酸
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
农药列管产品
此项目有
Pablo J Maid et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 24(4), 177-182 (2017-12-13)
Biologic agents may induce immune responses that could impact drug action. The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit
Yutaka Osuga et al.
Obstetrics and gynecology, 133(3), 423-433 (2019-02-12)
To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment
Régis Peffault de Latour et al.
British journal of haematology, 191(3), 476-485 (2020-05-26)
Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 36147-100MG | 04061831824230 |